|
"yen c j"的相關文件
顯示項目 1-10 / 471 (共48頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國立成功大學 |
2023 |
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
|
Ren, Z.;Ducreux, M.;Abou-Alfa, G.K.;Merle, P.;Fang, W.;Edeline, J.;Li, Z.;Wu, L.;Assenat, E.;Hu, S.;Rimassa, L.;Zhang, T.;Blanc, J.-F.;Pan, H.;Ross, P.;Yen, C.-J.;Tran, A.;Shao, G.;Bouattour, M.;Chen, Y.;Meyer, T.;Hou, J.;Tougeron, D.;Bai, Y.;Hou, M.-M.;Meng, Z.;Wu, J.;Li, V.;Chica-Duque, S.;Cheng, A.-L. |
| 國立成功大學 |
2023 |
The impact of preoperative waiting time in Stage II–III gastric or gastroesophageal junction cancer: A population-based cohort study
|
Yen, C.-C.;Yang, Yang Y.-H.;Ku, H.-Y.;Hu, Hu H.-M.;Lo, S.-S.;Chang, H.-C.;Chao, Y.;Chen, J.-S.;Wang, H.-P.;Wang, T.-E.;Bai, L.-Y.;Wu, M.-S.;Yen, C.-J.;Chen, L.-T.;Shan, Y.-S. |
| 國立成功大學 |
2023 |
Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study
|
Hsu, C.;Chang, Y.-F.;Yen, C.-J.;Xu, Y.-W.;Dong, M.;Tong, Y.-Z. |
| 國立成功大學 |
2023 |
ASO Visual Abstract: Distinct Failure Patterns in Hypopharyngeal Cancer Patients Receiving Surgery-Based Versus Radiation-Based Treatment
|
Lin, Y.-H.;Hsiao, J.-R.;Wu, Y.-H.;Chang, J.S.;Ou, C.-Y.;Lee, W.-T.;Huang, C.-C.;Chang, Chang C.-C.;Lai, Y.-H.;Tsai, S.-T.;Hsueh, W.-T.;Yen, C.-J.;Lin, C.-L.;Chen, Y.-S.;Jiang, S.-S.;Su, Y.-C.;Wu, S.-Y. |
| 國立成功大學 |
2023 |
Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways
|
Chen, Y.-T.;Masbuchin, A.N.;Fang, Y.-H.;Hsu, L.-W.;Wu, S.-N.;Yen, C.-J.;Liu, Y.-W.;Hsiao, Y.-W.;Wang, J.-M.;Rohman, M.S.;Liu, P.-Y. |
| 國立成功大學 |
2023 |
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
|
Chan, A.T.C.;Lee, V.H.F.;Hong, R.-L.;Ahn, M.-J.;Chong, W.Q.;Kim, S.-B.;Ho, G.F.;Caguioa, P.B.;Ngamphaiboon, Ngamphaiboon N.;Ho, C.;Aziz, M.A.S.A.;Ng, Q.S.;Yen, C.-J.;Soparattanapaisarn, N.;Ngan, R.K.-C.;Kho, S.K.;Tiambeng, M.L.A.;Yun, T.;Sriuranpong, V.;Algazi, Algazi A.P.;Cheng, A.;Massarelli, E.;Swaby, R.F.;Saraf, Saraf S.;Yuan, J.;Siu, L.L. |
| 國立成功大學 |
2023 |
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma The JUPITER-02 Randomized Clinical Trial
|
Mai, H.-Q.;Chen, Q.-Y.;Chen, D.;Hu, C.;Yang, K.;Wen, J.;Li, J.;Shi, Y.;Jin, F.;Xu, R.;Pan, J.;Qu, S.;Li, P.;Hu, C.;Liu, Y.-C.;Jiang, Y.;He, X.;Wang, H.-M.;Lim, W.-T.;Liao, W.;He, X.;Chen, X.;Wang, S.;Yuan, X.;Li, Q.;Lin, X.;Jing, S.;Chen, Y.;Lu, Y.;Hsieh, C.-Y.;Yang, M.-H.;Yen, C.-J.;Samol, J.;Luo, X.;Wang, X.;Tang, X.;Feng, H.;Yao, S.;Keegan, P.;Xu, R.-H. |
| 臺大學術典藏 |
2022-09-20T06:49:39Z |
Metabolic risks, white matter hyperintensities, and arterial stiffness in high-functioning healthy adults
|
Kuo H.-K.; Chen C.-Y.; Liu H.-M.; Yen C.-J.; Chang K.-J.; Chang C.-C.; Yu Y.-H.; Lin L.-Y.; HWANG, JUEY-JEN |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Chia-Chi Lin; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; Lee J.-H.; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
顯示項目 1-10 / 471 (共48頁)
1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
